Figure 6
From: CHK1 inhibition as a strategy for targeting fanconi anemia (FA) DNA repair pathway deficient tumors
FA specific tumoricidal activity of CHK1 inhibition in combination with Cisplatin (CDDP) treatment or ATM inhibition. (A) Seven day viability assay comparing the response of FANCF deficient 2008 ovarian cancer cells (bars 1, 3, 5, 7) versus FANCF corrected 2008F cells (bars 2, 4, 6, 8) to 25 uM CDDP (bars 3 and 4), and 25 uM CDDP + 100 nM Gö6976 (bars 11 and 12). Bars 1 and 2 represent DMSO only controls. When fit into the Chou-Talalay mutually nonexclusive modal [33], the Combination Index (CI) is 0.7, mathematically supporting a synergistic effect. (B) 7 day viability assay comparing the response of FANCF deficient 2008 ovarian cancer cells (bars 1, 3, 5, 7, 9, 11) versus FANCF corrected 2008F cells (bars 2, 4, 6, 8, 10, 12) to 10 uM KU-55933 (bars 3 and 4), 50 nM Gö6976 (bars 5 and 6), 100 nM (bars 7 and 8), 10 uM KU-55933 + 50 nM Gö6976 (bars 9 and 10), and 10 uM KU-55933 + 50 nM Gö6976 (bars 11 and 12). Bars 1 and 2 represent DMSO only controls. When fit into the Chou-Talalay mutually nonexclusive modal [33], the Combination Index (CI) is 0.9, mathematically supporting a synergistic effect.